{
    "root": "6054cc4c-402e-4a9d-ba06-f7e32c004abc",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ZEJULA",
    "value": "20240502",
    "ingredients": [
        {
            "name": "NIRAPARIB TOSYLATE",
            "code": "195Q483UZD"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "zejula poly ( adp-ribose ) polymerase ( parp ) inhibitor indicated : • maintenance treatment adult patients advanced epithelial ovarian , fallopian tube , primary peritoneal cancer complete partial response first-line platinum-based chemotherapy . ( 1.1 ) • maintenance treatment adult patients deleterious suspected deleterious germline brca -mutated recurrent epithelial ovarian , fallopian tube , primary peritoneal cancer complete partial response platinum-based chemotherapy . select patients therapy based fda-approved companion diagnostic zejula ( 1.2 , 2.1 )",
    "contraindications": "• first-line maintenance treatment advanced ovarian cancer : patients weighing < 77 kg ( < 170 lbs ) platelet count < 150,000/mcl , recommended 200 mg taken orally daily . ( 2.2 ) patients weighing ≥77 kg ( ≥170 lbs ) platelet count ≥150,000/ mcl , recommended 300 mg taken orally daily . ( 2.2 ) • maintenance treatment recurrent germline brca-mutated ovarian cancer : recommended 300 mg taken orally daily . ( 2.2 ) • continue treatment disease progression unacceptable toxicity . ( 2.2 ) • zejula may taken without food . ( 2.2 ) • , consider interruption treatment , dose reduction , dose discontinuation . ( 2.3 ) • patients moderate hepatic impairment , reduce starting niraparib 200 mg daily . ( 2.4 )",
    "warningsAndPrecautions": "zejula available oval-shaped , film-coated tablets containing 100 mg , 200 mg , 300 mg niraparib free base . zejula 100-mg tablets gray , debossed “ 100 ” one side “ zejula ” side . bottle 30 tablets ( ndc 0173-0909-13 ) . zejula 200-mg tablets blue , debossed “ 200 ” one side “ zejula ” side . bottle 30 tablets ( ndc 0173-0912-13 ) . zejula 300-mg tablets green , debossed “ 300 ” one side “ zejula ” side . bottle 30 tablets ( ndc 0173-0915-13 ) . store dispense original bottle . store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "none .",
    "indications_original": "ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. ( 1.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA ( 1.2 , 2.1 )",
    "contraindications_original": "• First-line maintenance treatment of advanced ovarian cancer: o For patients weighing <77 kg (<170 lbs) OR with a platelet count <150,000/mcL, the recommended dosage is 200 mg taken orally once daily. ( 2.2 ) o For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily. ( 2.2 ) • Maintenance treatment of recurrent germline BRCA-mutated ovarian cancer: The recommended dosage is 300 mg taken orally once daily. ( 2.2 ) • Continue treatment until disease progression or unacceptable toxicity. ( 2.2 ) • ZEJULA may be taken with or without food. ( 2.2 ) • For adverse reactions, consider interruption of treatment, dose reduction, or dose discontinuation. ( 2.3 ) • For patients with moderate hepatic impairment, reduce the starting dosage of niraparib to 200 mg once daily. ( 2.4 )",
    "warningsAndPrecautions_original": "ZEJULA is available as oval-shaped, film-coated tablets containing 100 mg, 200 mg, or 300 mg of niraparib free base.\n                  ZEJULA 100-mg tablets are gray, debossed with “100” on one side and “Zejula” on the other side. Bottle of 30 tablets (NDC 0173-0909-13).\n                  ZEJULA 200-mg tablets are blue, debossed with “200” on one side and “Zejula” on the other side. Bottle of 30 tablets (NDC 0173-0912-13).\n                  ZEJULA 300-mg tablets are green, debossed with “300” on one side and “Zejula” on the other side. Bottle of 30 tablets (NDC 0173-0915-13).\n                  Store and dispense in the original bottle. Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "None."
}